First AD

Second AD

Genital Mycotic Infection Treatment and Adverse Effects

In a patient with type 2 diabetes who develops a genital mycotic infection while on an SGLT-2 inhibitor, do you treat the infection with topical antifungals and continue the SGLT-2 inhibitor, or should the SGLT-2 inhibitor be discontinued?

A patient on a GLP-1 receptor agonist and RAAS inhibitor is experiencing bloating, nausea, and weight loss and expresses a desire to stop treatment. How should you address their concerns and manage these adverse effects while considering the benefits of continued therapy?

Enhancing CKD Care in Type 2 Diabetes: Bridging Gaps in Diagnosis, Treatment, and Patient Outcomes

HCPLive® Peer Exchange panel discussions feature authoritative insights, opinions, and perspectives on important issues facing today's care professionals.

Peer Exchange

Managing a genital mycotic infection in a patient with type 2 diabetes on an SGLT-2 inhibitor involves treating the infection with topical antifungals while generally continuing the SGLT-2 inhibitor, unless severe or recurrent infections occur. For a patient on a GLP-1 receptor agonist and RAAS inhibitor experiencing bloating, nausea, and weight loss, it is crucial to address their concerns by discussing the benefits of continued therapy, potential dose adjustments, or alternative treatments to mitigate adverse effects while maintaining therapeutic efficacy.

Panelists discuss the treatment of a patient with type 2 diabetes who develops a genital mycotic infection while on an SGLT-2 inhibitor, weighing the options of treating with topical antifungals versus discontinuing the medication, as well as addressing concerns for a patient on a GLP-1 receptor agonist and RAAS inhibitor who is experiencing adverse effects such as bloating and nausea while considering the benefits of continuing therapy.